Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma

Cholangiocarcinoma is the second most common liver cancer after hepatocellular carcinoma. In case of metastatic or unresectable disease, the recommended first-line treatment is gemcitabine-based doublet, most commonly gemcitabine and cisplatin. There is no standard treatment for further lines. MET f...

Descripción completa

Detalles Bibliográficos
Autores principales: Turpin, Anthony, Descarpentries, Clotilde, Grégoire, Valérie, Farchi, Olivier, Cortot, Alexis B, Jamme, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847551/
https://www.ncbi.nlm.nih.gov/pubmed/36434677
http://dx.doi.org/10.1093/oncolo/oyac194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847551/
https://www.ncbi.nlm.nih.gov/pubmed/36434677
http://dx.doi.org/10.1093/oncolo/oyac194

Ejemplares similares